NCT05354232 Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)
| NCT ID | NCT05354232 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Attention Deficit Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2022-07-01 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2022-07-01 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators are investigating whether home-based tDCS over the course of four weeks can improve ADHD symptom severity and improve dysexecutive functioning (cognitive control). Further, the investigators are investigating whether there is a dose-dependent response to tDCS.
Eligibility Criteria
Inclusion Criteria: 1. Male and female outpatients 18-65 years of age 2. A diagnosis of ADD/ADHD or meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. Exclusion Criteria: 1. Contraindication to tDCS: history or epilepsy, metallic implants in the head and neck, brain stimulators, vagus nerve stimulators, VP shunt, pacemakers, pregnancy. 2. Active substance dependence (except for tobacco). 3. Pregnant or nursing females. 4. Inability to participate in testing procedures. 5. Premorbid neurological conditions (including neurovascular and neurodegenerative diseases such as traumatic brain injury, stroke, Parkinson's, AD and other dementias) and severe psychiatric disorders (bipolar disorder, schizophrenia).
Contact & Investigator
Joan Camprodon, MD, PHD, MPH
PRINCIPAL INVESTIGATOR
MGB: Division of Neuropsychiatry and Neuromodulation
Frequently Asked Questions
Who can join the NCT05354232 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Attention Deficit Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05354232 currently recruiting?
Yes, NCT05354232 is actively recruiting participants. Contact the research team at mghdnn@mgh.harvard.edu for enrollment information.
Where is the NCT05354232 trial being conducted?
This trial is being conducted at Charlestown, United States.
Who is sponsoring the NCT05354232 clinical trial?
NCT05354232 is sponsored by Massachusetts General Hospital. The principal investigator is Joan Camprodon, MD, PHD, MPH at MGB: Division of Neuropsychiatry and Neuromodulation. The trial plans to enroll 60 participants.